Literature DB >> 12352802

Standard and alternative regimens of Haemophilus influenzae type b conjugate vaccine (polyribosylribitol phosphate-tetanus toxoid conjugate vaccine) elicit comparable antibody avidities in infants.

James D Campbell1, Rosanna Lagos, Myron M Levine, Genevieve A Losonsky.   

Abstract

BACKGROUND: Haemophilus influenzae type b conjugate vaccines are relatively expensive in the developing world. Previous study of the type b conjugate vaccine polyribosylribitol phosphate-tetanus toxoid conjugate vaccine showed that two dose and fractional three dose schedules elicit protective antibody concentrations equivalent to three full doses.
METHODS: Antibody avidity was measured in 73 of these vaccinees with a modified enzyme-linked immunosorbent assay using NH(4) SCN as the chaotrope. Avidity index (AI) is the molarity causing a 50% reduction in OD(405).
RESULTS: The postprimary series AI was similar for all dosing regimens. Preboost AI was highest in those receiving three half-doses, although there was no statistical difference among groups. Rises in avidity from age 8 to 12 months were also similar among regimens. Our data support the equivalence of anti-polyribosylribitol phosphate IgG avidity in infants primed with these alternative regimens.
CONCLUSIONS: Given the known correlation of avidity with assays of bacterial killing and memory priming, these potentially more economical alternative schedules should be studied in the developing world.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12352802     DOI: 10.1097/00006454-200209000-00007

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  4 in total

1.  Naturally acquired and conjugate vaccine-induced antibody to Haemophilus influenzae type b (Hib) polysaccharide in Malian children: serological assessment of the Hib immunization program in Mali.

Authors:  Julia Hutter; Marcela F Pasetti; Doh Sanogo; Milagritos D Tapia; Samba O Sow; Myron M Levine
Journal:  Am J Trop Med Hyg       Date:  2012-06       Impact factor: 2.345

2.  The immunogenicity and safety of a reduced PRP-content DTPw-HBV/Hib vaccine when administered according to the accelerated EPI schedule.

Authors:  Sukanta Chatterjee; Sylvan J Rego; Fulton D'Souza; B D Bhatia; Alix Collard; Sanjoy K Datta; Jeanne-Marie Jacquet
Journal:  BMC Infect Dis       Date:  2010-10-15       Impact factor: 3.090

3.  Primary and booster vaccination in Latin American children with a DTPw-HBV/Hib combination: a randomized controlled trial.

Authors:  Felix Espinoza; Miguel Tregnaghi; Angela Gentile; Katia Abarca; Javier Casellas; Alix Collard; Inge Lefevre; Jeanne-Marie Jacquet
Journal:  BMC Infect Dis       Date:  2010-10-15       Impact factor: 3.090

4.  Immunogenicity and Reactogenicity following Primary Immunisation with a Combined DTaP-HBV Vaccine and a Haemophilus influenzae Type B Vaccine Administered by Separate or Mixed Injection.

Authors:  G Gabutti; G Bona; P Dentico; F Bamfi; K Hardt; S Majori; P Crovari
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.